[Role of Chemotherapy in head and neck cancer].
For head and neck cancer, a recent meta-analysis of published randomized trial results showed that concurrent chemoradiotherapy, adjuvant chemotherapy and neoadjuvant chemotherapy may increase absolute survival by 12.1%, 6.5%, and 3.7%, respectively. Initial response rates to first line chemotherapy are high, but this responsiveness does not appear to translate into a survival benefit. Thus, chemotherapy can be indicated as the standard therapy for a very limited range of advanced head and neck cancers. With the aim of prolonging survival, N stage advanced nasopharyngeal cancer is a good candidate for neoadjuvant chemotherapy. Among a large number of randomized trials of neoadjuvant chemotherapy, organ function preservation studies showed the possibility of laryngeal preservation for locally resectable T2 and T3 laryngeal and hypopharyngeal cancer. Concurrent chemoradiotherapy may be indicated for advanced T stage head and neck cancers, especially those with locally unresectable lesions. For N stage advanced pharyngeal cancer patients, adjuvant chemotherapy with applied after the standard therapy has a role in the treatment. With palliative treatment in advanced and/or recurrent disease, there is less benefit from chemotherapy and indications for chemotherapy should be selected for individual patients.